Wilson Sonsini Goodrich & Rosati has advised 4E Therapeutics. 4E Therapeutics, an Austin-based neuroscience company, has announced its acquisition by Eli Lilly and Company (NYSE: LLY)....
Eli Lilly Acquires 4E Therapeutics to Expand Chronic Pain Treatment Portfolio
Resmed Acquires Noctrix Health for $340 Million to Expand Sleep Health Portfolio
DLA Piper has advised Resmed. Wilson Sonsini Goodrich & Rosati has advised Noctrix Health. Resmed has completed the acquisition of Noctrix Health, Inc. for $340 million,...
ABL Bio Announces Equity Investment Agreement with Lilly
Wilson Sonsini Goodrich & Rosati has advised ABL Bio. ABL Bio has announced the signing of an equity investment agreement valued at KRW 22 billion with...
Materna Medical Secures $20 Million Series B2 Financing Round
Wilson Sonsini Goodrich & Rosati has advised Materna Medical on the transaction. Materna Medical, Inc., an innovator in women’s pelvic health solutions, has announced the completion...
Biolog’s Acquisition of Anaerobe Systems
Wilson Sonsini Goodrich & Rosati advised Anaerobe Systems on the transaction. Biolog, a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification...
Neptune Medical’s $97 Million Series D Financing
Wilson Sonsini Goodrich & Rosati advised Neptune Medical on the transaction. Neptune Medical, a leader in medical device innovation, announced the closing of a $97 million...
Senzime’s $44 Million Acquisition of Respiratory Motion
Wilson Sonsini advised Respiratory Motion on the deal. Senzime completed the acquisition of 100 percent of the shares in Respiratory Motion, as was made public on...